India’s API Industry Manufacturing Leadership Talent 2024
API Industry in India
The Active Pharmaceutical Ingredient (or API) industry is a crucial segment of the Indian pharma industry (which is anticipated to reach USD 65 billion by 2024) and contributes to around 35 per cent of the pharma market. India is the 3rd largest producer of APIs accounting for an 8 per cent share of the Global API Industry. 500+ different APIs are manufactured in India, and it contributes 57 per cent of APIs to the prequalified list of the WHO.
The growing antagonism between the West and China has also pushed the global pharma majors to source more from countries other than China. India’s emergence as the alternate source of bulk drugs has been quite remarkable.
To capitalize on its API potential, India is building a holistic and conducive ecosystem. In 2020, the government approved INR 6,940 crore for a production-linked incentive (PLI) scheme for the promotion of domestic manufacturing of Key Starting Materials (KSMs) / Drug Intermediaries (DIs), and APIs.
Over the next several years, the Indian API market is anticipated to increase at a CAGR of 13.7 per cent. The Indian API space has become lucrative for several investors and venture capitalists. India’s robust domestic market, advanced chemical industry, skilled workforce, stringent quality and manufacturing standards, and low costs (about 40 per cent less than that in the West) for setting up and operating a modern plant give an added advantage.
Read More: India’s API Industry Manufacturing Leadership Talent 2024
Comments
Post a Comment